Spruce Biosciences Files 8-K: Routine Corporate Info Update

TL;DR

**Spruce Biosciences filed a routine 8-K, updating basic corporate info and confirming its Nasdaq listing.**

AI Summary

Spruce Biosciences, Inc. filed an 8-K on January 8, 2024, reporting an event that occurred on January 4, 2024. This filing indicates a routine update regarding their corporate information, specifically their address at 611 Gateway Boulevard, Suite 740, South San Francisco, California 94080, and their trading symbol SPRB on the Nasdaq Global Select Market. This matters to investors because it confirms the company's continued compliance with SEC reporting requirements and provides up-to-date contact and listing information, which is foundational for any investment decision.

Why It Matters

This filing is a standard regulatory update, confirming Spruce Biosciences' operational details and listing status, which is important for maintaining transparency and investor confidence.

Risk Assessment

Risk Level: low — This 8-K is a standard administrative filing and does not contain any information that would indicate a significant change in the company's risk profile.

Analyst Insight

A smart investor would note this filing as a routine compliance update, confirming the company's basic operational and listing details, but would not base investment decisions solely on this administrative report. Further research into financial performance and pipeline developments would be necessary.

Key Numbers

• $0.0001 — par value per share (This is the nominal value assigned to each share of common stock by Spruce Biosciences, Inc.)

Key Players & Entities

• Spruce Biosciences, Inc. (company) — the registrant filing the 8-K
• January 4, 2024 (date) — date of the earliest event reported
• January 8, 2024 (date) — date the 8-K was filed
• 611 Gateway Boulevard, Suite 740, South San Francisco, California 94080 (address) — principal executive offices of Spruce Biosciences
• SPRB (company) — trading symbol for Spruce Biosciences
• Nasdaq Global Select Market (company) — exchange where Spruce Biosciences' common stock is registered
• $0.0001 (dollar_amount) — par value per share of common stock

Forward-Looking Statements

• Spruce Biosciences will continue to maintain its listing on the Nasdaq Global Select Market. (Spruce Biosciences, Inc.) — high confidence, target: 2025-01-08

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 per share SPRB Nasdaq Global Select
• $96 million — of December 31, 2023 were approximately $96 million. This amount is unaudited and prelimina

Filing Documents

• sprb-20240104.htm (8-K) — 66KB
• sprb-ex99_1.htm (EX-99.1) — 27KB
• sprb-ex99_2.htm (EX-99.2) — 38KB
• img25151992_0.jpg (GRAPHIC) — 8KB
• img26075513_0.jpg (GRAPHIC) — 8KB
• 0000950170-24-002704.txt ( ) — 294KB
• sprb-20240104_pre.xml (EX-101.PRE) — 11KB
• sprb-20240104_lab.xml (EX-101.LAB) — 18KB
• sprb-20240104.xsd (EX-101.SCH) — 2KB
• sprb-20240104_htm.xml (XML) — 5KB

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. On January 4, 2024, Spruce Biosciences, Inc. (the “Company”) issued a press release providing a corporate update that included updates on its clinical programs, anticipated upcoming milestones, and an estimate that its cash and cash equivalents as of December 31, 2023 were approximately $96 million. This amount is unaudited and preliminary and is subject to completion of financial closing procedures. Additional information and disclosure would be required for a more complete understanding of the Company’s financial position and results of operations as of December 31, 2023. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. All of the information furnished in this Item 2.02 and Item 9.01 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended (“Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On January 5, 2024, the Company issued a press release reporting baseline characteristics of patients enrolled in the Company’s Phase 2b CAHmelia-203 and CAHmelia-204 clinical trials of tildacerfont for the treatment of adult classic congenital adrenal hyperplasia (“CAH”). A copy of the press release is furnished as Exhibit 99.2 hereto. All of the information furnished in this Item 7.01 and Item 9.01 (including Exhibit 99.2) shall not be deemed to be “filed” for purposes of Section 18 of the Exchange Act and shall not be incorporated by reference in any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

01 Other Events

Item 8.01 Other Events. As noted in Item 7.01, on January 5, 2024, the Company issued a press release reporting baseline characteristics of patients enrolled in the Company’s Phase 2b CAHmelia-203 and CAHmelia-204 clinical trials of tildacerfont for the treatment of adult classic CAH: CAHmelia Adult Classic CAH Program Baseline Characteristics Study Characteristics CAHmelia-203 (N = 96) CAHmelia-204 (N = 98) 1 Male/Female (Proportion of Total Subjects) 47% Male 53% Female 47% Male 53% Female Average Age Age Ranges 32 Years Old (18 – 65 Years Old) 33 Years Old (18 – 64 Years Old) Average Baseline Glucocorticoid (GC) Dose 2 27 mg/day (14 mg/ m 2 /day) 35 mg/day (19 mg/ m 2 /day) Average Baseline Androstenedione (A4) Level 3 1,149 ng/dL 214 ng/dL Body Mass Index (BMI) 50% Obese (BMI ≥ 30 kg/m 2 ) 53% Obese (BMI ≥ 30 kg/m 2 ) 1 Patients enrolled as of December 20, 2023. Final enrollment is anticipated to be completed in January 2024 and projected between 98 and 100 patients. 2 In hydrocortisone equivalents (HCe) 3 Pre-GC dose.

Forward Looking Statements

Forward Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, the results, conduct, progress and timing of the Company’s clinical trials. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they prove incorrect or do not fully materialize, could cause the Company’s results to differ materially from those expressed or implied by such forward-looking statements, including, but not limited to, risks and uncertainties related to: topline data may not reflect the complete or final results of a particular study or trial, and are subject to change; the Company’s ability to advance, obtain regulatory approval of and ultimately commercialize its product candidates; the timing and results of preclinical and clinical trials; the risk that positive results in a clinical trial may not be replicated in subsequent trials or successes in early stage clinical trials may not be predictive of results in later stage trials and preliminary interim data readouts of ongoing trials may show results that change when such trials are completed; the Company’s ability to fund development activities and achieve development goals; the Company’s ability to protect its intellectual property; the direct and indirect impacts of geopolitical and macroeconomic events on the Company’s business; and other risks and uncertainties described under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, its subsequently filed Quarterly Reports on Form 10-Q, and the other documents the Company files from time to time with the U.S. Securities and Exchange Commission (“SEC”). These forward-looking statements speak only as of the date of this Current Re

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release of Spruce Biosciences, Inc., dated January 4, 2024. 99.2 Press Release of Spruce Biosciences, Inc., dated January 5, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. SPRUCE BIOSCIENCES, INC. Date: January 8, 2024 By: /s/ Samir Gharib Samir Gharib President and Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR